Resting Energy Expenditure in Palliative Cancer Patients

The study purpose is to measure REE by indirect calorimetry and to determine limits of agreement with confidence intervals between measured REE and predictive equations for determination of energy requirements in patients with incurable cancer. Clinical factors associated with hyper- and hypometabolism will be elucidated. Data will be obtained from patient journals in combination with measurements of REE and registration of survival. Data will be collected at one timepoint and survival will be monitored prospectively.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Cancer Body Weight Body Weight Changes Cachexia Neoplasms Pathological Conditions, Signs and Symptoms Signs and Symptoms Thinness Weight Loss

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital

Trondheim, 7021, Norway

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

A verified diagnosis of an incurable malignant disease
Hospitalized at the Cancer clinic, St. Olavs Hospital
≥ 18 years of age
Able to provide written informed consent
Able to comply with all study procedures

Exclusion criteria

Cognitive impairment
In need of supplementary oxygen
Receiving invasive or noninvasive ventilation

Treatment and study plan

Primary outcomes

Measurement of resting energy expenditure (REE) in patients with incurable cancer measured with the COSMED Q-NRG+ Indirect Calorimeter with a Canopy Hood.

Time frame: Throughout study completion, approximately 3 years.

Investigate the agreement between the most used energy expenditure prediction equation (Harris-Benedict calculation for resting energy expenditure based on weight, height and gender) and measured REE (kilocalories/day) by indirect calorimetry in patients with incurable cancer.

Secondary outcomes

Clinical factors associated with hyper- and hypometabolism

Time frame: Throughout study completion, approximately 3 years.

Explore the association between patients identified as hyper-or hypometabolic (REE > 10% or < 10% of the predicted BMR (in kilocalories per day)) and a set of explanatory variables such as cancer diagnosis (type), weight loss last six months ((current/past weight)*100), symptom score (Edmonton Symptom Assessment System (ESAS)), degree of inflammation (CRP in mg/L), and survival (days after REE measurement).

Sponsors and collaborators

Lead sponsor

Norwegian University of Science and Technology

Other

Collaborators

St. Olavs Hospital
UiT The Arctic University of Norway

Registry information

Official study title

Resting Energy Expenditure in Palliative Cancer Patients (REPAT) - an Explorative Study in Patients With Incurable Cancer

Acronym: REPAT

Important dates

Study start: 2023
Primary completion: 2025
Study completion: 2026
First posted: Jan 16, 2024
Registry last updated: Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting